The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

A vizsgálat adatai

Ki végzi

Boston Scientific Corporation

Azonosító

NCT03551496

A regiszteradat frissítve

2024. július 1.

Eredeti leírás

Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).A teljes eredeti leírásKevesebb

A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia

Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).

Bevonási feltételek: Subject is 18 years or older and has signed and dated the trial informed consent form (ICF); Subject is willing and able to comply with the trial testing, procedures and follow-up schedule; Subject has chronic, symptomatic lower limb ischemia, determined by Rutherford categories 4 or 5 in the target limb, with wound(s) confined to toes/forefoot; Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator; Intra-procedure Inclusion Criteria:; Stenotic, restenotic or occlusive target lesion(s) located in the tibioperoneal trunk, anterior tibial, posterior tibial and/or peroneal artery(ies); Target lesion(s) must be at least 4cm above the ankle joint; A single target lesion per vessel, in up to 2 vessels, in a single limb; Degree of stenosis ≥ 70% by visual angiographic assessment; Reference vessel diameter is between 2.5 - 3.25mm for phase A RCT; Total target lesion length (or series of lesion segments) to be treated is ≤ 70 mm for phase A RCT prior to the data monitoring committee's approval for stent overlap. (Note: Lesion segment(s) must be fully covered with one DES BTK stent, if randomized to stent); Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm for phase A RCT after the data monitoring committee's approval for stent overlap (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents, if randomized to stent); Target vessel(s) reconstitute(s) at or above the stenting limit zone (4cm above the ankle joint); Target lesion(s) is located in an area that may be stented without blocking access to patent main branches; Treatment of all above the knee inflow lesion(s) is successful prior to treatment of the target lesion; Guidewire has successfully crossed the target lesion(s).

Kizáró feltételek: Stroke ≤ 90 days prior to the procedure date; Prior or planned major amputation in the target limb; Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass); Previously implanted stent in the target vessel(s); Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date; History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date; Subject is currently taking Canagliflozin; Contraindication to anticoagulation or antiplatelet therapy; Known allergy to contrast media that cannot be adequately pre-medicated prior to the interventional procedure; Subject is on a high dose of steroids or is on immunosuppressive therapy; Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team); Intra-procedure Exclusion Criteria; Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s), (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy); NYHA class IV heart failure; Subject has symptomatic coronary artery disease (ie, unstable angina); Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease, vasculitis); Coagulation disorder, including hypercoagulability; Known allergies to stent or stent components; Known hypersensitivity to heparin; Renal failure as measured by a GFR ≤ 30ml/min per 1.73m2, measured ≤ 30 days prior to the procedure date; Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure date; Life expectancy ≤ 1year; Body Mass Index (BMI) <18; Active septicemia or bacteremia; Angiographic evidence of intra-arterial acute/subacute thrombus or presence of atheroembolism; Treatment required in > 2 target vessels (Note: a target lesion originating in one vessel and extending into another vessel is considered 1 target vessel); Aneurysm is present in the target vessel(s); Extremely calcified lesions.

ClinicalTrials.gov NCT03551496